

# 集團發展歷程



## 基亞生物 (MBC) 成立

2024 異體NK細胞治療臨床試驗核准  
2021 自體NK細胞治療臨床試驗核准  
2020 Magicell-NK通過台灣特管法  
2019 引進日本MEDINET公司 $\gamma\delta$ T細胞技術  
2011 台灣上櫃掛牌 (TPEX 3176)  
2008 與日本Oncolys公司共同開發OBP-301  
2002 執行PI-88臨床試驗  
1999 基亞生物科技成立

1999

2006



## 高端疫苗 (MVC) 分拆成立

2023 腸病毒 EV71台灣核准上市  
2021 新冠疫苗通過台灣緊急使用核准  
2018 台灣上櫃掛牌 (TPEX 6547)  
2014 建立細胞培養系統生產廠  
2012 分拆設立新公司  
2009 基亞內部成立新事業單位

2009

2014

2020 新冠肺炎檢測試劑通過台灣及美國緊急使用核准  
2015 分拆設立新公司  
2014 建立廈門生產廠  
2007 通過ASHI認證  
2006 基亞收購Texas BioGene  
1999 德州Texas BioGene成立



## 德必碁 (TBG) 分拆成立



## 收購溫士頓 (Winston)

2021 台灣興櫃掛牌 (TPEX 6817)  
2018 通過優良運銷規範 (GDP)  
2016 化妝品廠通過ISO22716認證  
2015 通過PIC/S GMP符合性評鑑  
2014 基亞收購股權  
1974 溫士頓成立

# Corporate History



## Medigen (MBC) Founded

2024 Allo-NK trial IND approval (TW)  
2021 Auto-NK trial IND approval (TW)  
2020 Magicell-NK authorized (TW Special Regulation)  
2019  $\gamma\delta$ T Licensed from MEDINET (JP)  
2011 Listed on OTC (TPEX 3176)  
2008 Collaborated with Oncolys (JP)  
2002 Started PI-88 trial  
1999 Medigen founded

1999

2006



## MVC Spun off and Founded

2023 EV71 vaccine received TFDA approval  
2021 COVID-19 vaccine received TFDA EUA  
2018 Listed on OTC (TPEX 6547)  
2014 Cell-based vaccine plant established  
2012 Spun off  
2009 New business unit in MBC

2009

2014

2020 COVID-19 qPCR testing kits  
accredited EUA (TW, USA)

2015 Spun off  
2014 Xiamen plant established  
2007 Received ASHI accreditation  
2006 MBC acquired Texas BioGene  
1999 Texas BioGene founded



## TBG Spun off and Founded



## WINSTON Acquired by MBC

2021 Listed on the  
OTC Emerging Market (TPEX 6817)  
2018 Good Distribution Practice obtained  
2016 Cosmetic factory ISO22716 certified  
2015 PIC/S GMP obtained  
2014 MBC acquired 68% stake  
1974 WINSTON founded